VJHemOnc is committed to improving our service to you

ASH 2019 | Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results

VJHemOnc is committed to improving our service to you

Jean-Jacques Kiladjian

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the results from the long-term use of ropeginterferon alpha-2b (ropeg) in polycythemia vera (PV). Data shows ropeg minimizes the occurrence of thromboembolic events and is capable of inducing deep molecular responses, unlike hydroxyurea. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter